Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (TRVI) is a clinical-stage biopharmaceutical company advancing Haduvio™, an investigational oral therapy targeting chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), along with pruritic conditions like prurigo nodularis. This page provides comprehensive access to official company announcements, clinical trial updates, and strategic developments.
Investors and industry professionals will find curated updates on TRVI's research programs, regulatory milestones, and financial performance. Our news collection includes details on Haduvio's dual opioid receptor mechanism, trial design specifics, and collaborative initiatives – all essential for evaluating the company's scientific and commercial trajectory.
Key content categories include clinical trial results, FDA communications, intellectual property updates, executive leadership changes, and financial disclosures. Each update is presented with contextual clarity to serve both expert analysts and those new to biopharma investing.
Bookmark this page for streamlined access to TRVI's evolving story as it progresses through critical development phases. Check regularly for verified updates on therapeutic advancements directly from company filings and authorized communications.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced significant advancements in its clinical development for Haduvio, targeting chronic cough in idiopathic pulmonary fibrosis (IPF) and chronic pruritus in prurigo nodularis (PN). The Phase 2 CANAL trial demonstrated a 77.3% reduction in cough frequency, leading to expedited development. The company completed a private placement raising $55 million to fund further clinical trials. As of March 31, 2022, Trevi reported $29.1 million in cash and cash equivalents and a net loss of $7.3 million for the quarter.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call on May 12, 2022, at 4:30 p.m. EDT to discuss its Q1 2022 financial results and provide a corporate update. The call can be accessed via phone or through a live audio webcast on the company's website. Trevi is focused on developing Haduvio™, an investigational therapy aimed at treating pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis. Haduvio has received Fast Track designation from the FDA for its proposed indication.
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, will present at two significant events in May 2022. The LifeSci Partners Immunology & Inflammation Symposium is scheduled for May 11, featuring Jennifer Good (President and CEO) and Dr. Bill Forbes (CDO). Additionally, Trevi will participate in the H.C. Wainwright Global Investment Conference from May 23-26, with a virtual presentation on May 24. Trevi is developing Haduvio (nalbuphine ER) for treating chronic pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis.
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, from 10:15 a.m. to 10:55 a.m. EDT. CEO Jennifer Good and Dr. Bill Forbes will discuss the investigational therapy Haduvio for treating pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis. The event will be available via live webcast on the company’s website, with an archived replay accessible for 30 days.
Trevi recently reported significant results from its CANAL trial, showing a 77% reduction in daytime cough frequency.
Trevi Therapeutics (Nasdaq: TRVI) announced a private placement to raise approximately $55 million through the sale of 4,580,526 shares at $1.90 each and pre-funded warrants at $1.899. The funds will support the clinical development of Haduvio for chronic cough in idiopathic pulmonary fibrosis (IPF) and for working capital. The deal, led by Frazier Life Sciences and Venrock Healthcare Capital Partners, is expected to close around April 11, 2022, pending customary conditions. The shares are unregistered under the Securities Act and will be resold upon effective registration.
Trevi Therapeutics (TRVI) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022. The fireside chat, featuring CEO Jennifer Good and CDO Bill Forbes, will take place from 8:00 a.m. to 8:40 a.m. EDT. The discussion will highlight findings from the Phase 2 CANAL trial, where Haduvio showed a 77% reduction in daytime cough frequency in patients with idiopathic pulmonary fibrosis. Additionally, top-line data from the Phase 2b/3 PRISM trial for pruritus in prurigo nodularis is anticipated in the second quarter of 2022.
Trevi Therapeutics (TRVI) announced a webinar on March 30, 2022, focusing on chronic cough in idiopathic pulmonary fibrosis (IPF) patients. Dr. William Forbes will discuss the challenges faced by IPF patients, including a lack of approved treatments for chronic cough, which affects up to 85% of the 130,000 estimated US patients. Trevi will present recent positive interim results from its Phase 2 CANAL trial of Haduvio (nalbuphine ER) aimed at addressing chronic cough in IPF. The webinar will also include a live Q&A session.
Trevi Therapeutics (Nasdaq: TRVI) has announced significant updates regarding its clinical trials and financial performance. The Phase 2 CANAL trial for Haduvio™ in treating chronic cough in idiopathic pulmonary fibrosis (IPF) showed a highly significant reduction in cough events (p < 0.0001), leading to early enrollment closure. Additionally, enrollment in the Phase 2b/3 PRISM trial for pruritus due to prurigo nodularis is complete, with top-line results expected by Q2 2022. For Q4 2021, Trevi reported a net loss of $8.5 million and had cash reserves of $36.8 million as of December 31, 2021.
Trevi Therapeutics concludes early enrollment for its Phase 2 CANAL trial, focusing on chronic cough in idiopathic pulmonary fibrosis (IPF). The trial's interim analysis revealed a statistically significant 77.3% reduction in daytime cough frequency with Haduvio™ (nalbuphine ER) compared to 25.7% with placebo (p<0.0001). A total of approximately 40 subjects were enrolled. Full efficacy and safety results are anticipated in Q3 2022, following the successful interim findings.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced a conference call on March 17, 2022, at 4:30 p.m. ET to review its Q4 and full year 2021 financial results. The company is focused on developing Haduvio (nalbuphine ER) for treating serious conditions. Currently, Trevi is conducting Phase 2b/3 trials for chronic pruritus linked to prurigo nodularis and a Phase 2 trial for chronic cough in idiopathic pulmonary fibrosis patients. Haduvio has been granted Fast Track designation by the FDA for its proposed use.
